ClinicalTrials.gg
RecruitingNCT04820361Updated May 12, 2023

Effect of Cannabinoids on Pain in Fabry Disease Patients

An interventional study of Cannabis sativa L., folium cum flore and Placebo in Pain, Neuropathic, sponsored by Albina Nowak, MD. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-12.

Sponsored by Albina Nowak, MD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Neuralgia with a site in Switzerland — 5 open to participants now, 5 under way, none of them phase 3. Neuralgia · Switzerland.

Planned enrollment
11th of 15
22 · median 30
Started
2022
with 1 other
No phase
5 of 20
3 open now
Registered
14th of 20
by date
Lead sponsor
1 of 20
Albina Nowak, MD

Among the 20 studies in Neuralgia with a site in Switzerland, this one is the 11th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 with no phase, and was the 14th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

5 of the 20 studies in Neuralgia with a site in Switzerland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Neuralgia with a site in Switzerland, or all of them as a file.
02

Study summary

Fabry Disease (FD) is a rare lysosomal storage disorder due to the absence or deficiency of hydrolase α-galactosidase A (α-Gal A) activity in lysosomes. This dysfunction results in progressive accumulation of glycosphingolipids in a wide variety of cells, resulting in major organ system damage.

Patients with Fabry disease can suffer from neuropathic pain, since lysosomal accumulation affects small unmyelinated nerve fibers. Neuropathic pain is one of the prominent and debilitating symptoms significantly interfering with life quality in FD patients. Current treatment of Fabry patients with neuropathic pain is deficient, as they respond poorly to a conventional pain therapy, often require a high-dose opioids treatment and presentation to the Emergency Department.

Sativex® has been shown to be a successful treatment option in neuropathic pain of different origin with minimal neuropsychological influence: in multiple sclerosis (MS), chemotherapy-induced neuropathic pain and other. It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) and has recently been licensed in Switzerland for treatment of neuropathic chronic pain in MS. Sativex® is an oral spray.

Read the detailed description

Fabry disease is an X-linked lysosomal storage disease caused by a deficiency of the enzyme α-galactosidase A. Patients suffering from Fabry's disease may suffer from neuropathic pain, since the lysosomal accumulation of lipids can also take place in the small nerve fibers. Typically, neuropathic pain occurs in late childhood or adolescence and disappears after several years, probably due to the irreversible destruction of the small nerve fibers. The pain management of Fabry patients suffering from neuropathic pain is inadequate, as patients often do not respond well to conventional pain therapies.

Aim of this study:

The aim of this study is to find out how strongly the investigational drug Sativex® (active ingredients: tetrahydrocannabinol (THC) and cannabidiol (CBD)) can influence the pain that can be caused by Fabry's disease. For this purpose, the investigational drug is compared with a placebo drug. The latter is a drug without an active ingredient. These studies provide us with important information on the origin of the pain and at the same time on the mechanism of action of Sativex®. This makes it possible to develop new forms of therapy in the future.

Procedure:

A total of 22-30 patients are divided into two groups of 11-15 patients each. Both groups will undergo the same test program. This will be divided into two phases: In the first phase, which will last 8 weeks, one group will receive Sativex® while the other group will receive a placebo. In the second phase, which will also last 8 weeks, the group that previously received the investigational drug will now receive the placebo and the previous placebo group will now receive the investigational drug. The study is double-blind, i.e. neither the patient nor the investigator knows who is receiving the investigational drug or the placebo. Patients are randomly assigned to the groups. Throughout the treatment, patients maintain their usual pain management regimen. (see Study Schedule) For 14 weeks, patients will fill out their pain diary daily. Every two weeks a blood sample is taken to determine the levels of cannabinoid metabolites. At the beginning, at the end of the first and after the second phase, the patient will fill out various questionnaires on neuropathic pain and improvement of quality of life. This will be used to assess whether pain relief is achieved.

Translated with www.DeepL.com/Translator (free version)

03

Conditions studied

  • Pain, Neuropathic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age: 18-70 years

      • Patients with genetically confirmed Fabry disease
      • On treatment with Enzyme Replacement Therapy (ERT)
      • Sufficient command of German language
      • Pain duration of more than 3 months
      • Stable analgesic regimen for at least 2 weeks preceding the study entry day
      • Baseline worst last week pain intensity ≥4 on numerical rating scale (NRS)
      • Signed and dated
      • ERT or chaperone therapy at a stable dose for at least 3 last months

Exclusion criteria

Exclusion Criteria:

    • Known or allergy to cannabinoids.

      • Women who are pregnant or breast feeding; intention to become pregnant during the course of the study, lack of safe , defined as: female subjects of , not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not willing or able to use any other second (additional) considered sufficiently reliable by the investigator in individual cases. Female subjects who are surgically sterilized/hysterectomized or for longer than 2 years are not considered as being of child bearing potential.
      • Dementia
      • Other pain not of neuropathic origin thought by the investigator to be of nature or severity to interfere with the patient's assessment of neuropathic pain due to Fabry disease.
      • Patients with known or suspected non-compliance, drug or alcohol abuse, including Marijuana cigarettes.
      • Patients with known schizophrenia, other psychotic disorders, personality disorders or another severe psychiatric disorder or positive family history with these disorders, except depression.
      • Patients with another disease (e.g. renal failure, hepatic dysfunction, severe cardiovascular or convulsive diseases).
      • Participation in another study with drugs within the 30 days preceding and during the present study.
      • Previous enrolment into the current study
      • Enrolment of the investigator, his/her family members, employees and other dependent persons.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
22 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    oral spray

    Drug: Placebo

  • Active comparator
    Sativex®

    .It contains Δ-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

    Drug: Cannabis sativa L., folium cum flore

Interventions

  • DrugCannabis sativa L., folium cum flore

    Muscle Relaxation

    Also known as: Spasmolytic

  • DrugPlacebo

    Muscle Relaxation

    Also known as: Spasmolytic

06

What researchers measure

Primary outcomes

  1. NRS

    NRS is a straightforward commonly used method to illustrate pain.

    Time frame: Daily NRS score after 28 days will be compared to baseline NRS score, evaluated before titration phase starts

Secondary outcomes

  1. QST

    Pain thresholds using the quantitative sensory testing.

    Time frame: At baseline and after 28 days of treatment with study drug and placebo, respectively.

  2. WHO-Quality of life score (WHOQOL-BREF)

    Improvement of quality of life.

    Time frame: Between baseline and treatment after 28 days.

  3. Patient global impression of change (PGIC)

    Improvement of quality of life.

    Time frame: For the average pain of treatment week 4.

  4. Short form McGrill Paint Questionnaire (SF-MPQ)

    Improvement of neuropathic pain.

    Time frame: Compared between baseline and average pain of treatment after 28 days.

  5. Douleur Neuropathic en 4 questions (DN4-Questionnaire)

    Improvement of neuropathic pain.

    Time frame: Compared between baseline and treatment week 4.

  6. Profile of Mood States (POMS questionnaire)

    Change in Profile of Mood States.

    Time frame: Between baseline and treatment week 4.

  7. Insomnia severity Index

    Change in Insomnia severity score.

    Time frame: Between baseline and treatment after 28 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003 Mar;102(1-2):1-8. doi: 10.1016/s0304-3959(03)00006-x. No abstract available. PubMed 12620591 ↗
  • Rolke R, Baron R, Maier C, Tolle TR, Treede -DR, Beyer A, Binder A, Birbaumer N, Birklein F, Botefur IC, Braune S, Flor H, Huge V, Klug R, Landwehrmeyer GB, Magerl W, Maihofner C, Rolko C, Schaub C, Scherens A, Sprenger T, Valet M, Wasserka B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006 Aug;123(3):231-243. doi: 10.1016/j.pain.2006.01.041. Epub 2006 May 11. Erratum In: Pain. 2006 Nov;125(1-2):197. PubMed 16697110 ↗
  • Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x. Epub 2014 Jan 13. PubMed 24420962 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.

Of 248 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 17 months is below that.

Counting every sponsor, half of 266 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Mar 29, 2021
StartActual
Jul 7, 2022
Primary completionEst.
Dec 29, 2023
CompletionEst.
Dec 29, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04820361
Lead sponsor
Albina Nowak, MD
Collaborators
Swiss National Science Foundation
Responsible party
Albina Nowak, MD (Sponsorl Investigator, University of Zurich) — Sponsor-investigator
First posted
Mar 29, 2021
Start date
Jul 7, 2022
Primary completion
Dec 29, 2023 (estimated)
Completion
Dec 29, 2023 (estimated)
Last update
May 12, 2023

Study contacts

Albina Nowak, PD
Contact
albina.nowak@usz.ch
+41432538872
Albina A Nowak, PH
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion